Acurx Pharmaceuticals, Inc.ACXPNASDAQ
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | -18.03% |
| Q2 2025 | -12.46% |
| Q1 2025 | -27.42% |
| Q4 2024 | -31.14% |
| Q3 2024 | -34.37% |
| Q2 2024 | 17.40% |
| Q1 2024 | -19.95% |
| Q4 2023 | 44.01% |
| Q3 2023 | -22.31% |
| Q2 2023 | 70.97% |
| Q1 2023 | -29.11% |
| Q4 2022 | -9.96% |
| Q3 2022 | 74.52% |
| Q2 2022 | 11.33% |
| Q1 2022 | 14.33% |
| Q4 2021 | -36.45% |
| Q3 2021 | 1085.36% |
| Q2 2021 | 3.44% |
| Q1 2021 | -79.91% |
| Q4 2020 | -30.67% |
| Q3 2020 | 64.69% |
| Q2 2020 | -41.48% |
| Q1 2020 | 0.00% |